14 research outputs found

    The Exilic age

    No full text
    Philadelphia160 p.; 21 c

    CliMA/Oceananigans.jl: v0.88.0

    No full text
    Oceananigans v0.88.0 Diff since v0.87.4 Merged pull requests: (0.88.0) MPI communication and computation overlap in the HydrostaticFreeSurfaceModel and NonhydrostaticModel (#3125) (@simone-silvestri) Linear time interpolation in FieldTimeSeries (#3236) (@simone-silvestri) Fill metrics for halo regions for OrthogonalSphericalShellGrid (#3239) (@navidcy) Fix docstring for RectilinearGrid grid metrics (#3255) (@navidcy) Cubed sphere tracer advection script (#3266) (@glwagner) Remove some type instabilities (#3271) (@navidcy) Closed issues: Overlapping computation and MPI halo communication (#615) Abstraction for configuring kernels (#3067) Offsetting kernel indices (#3068) Velocity profile of channel flow case has difference with log-law (#3195) OrthogonalSphericalShellGrid metrics and coordinates are missing values in halo points (#3198) Advection of tracer with prescribed or constant velocities over a ConformalCubedSphereGrid (#3204) Should grid be a positional argument to model constructors? (#3250) RectilinearGrid metrics are described wrong in the docstring (#3252) GPU illegal memory access (#3267) Does Oceananigans support coastal modelling? (#3269

    CliMA/Oceananigans.jl: v0.87.4

    No full text
    Oceananigans v0.87.4 Diff since v0.87.3 Merged pull requests: Deal with x ⇆ y, λ ⇆ φ, etc when filling halos for metrics/coords in ConformalCubedSphereGrid (#3256) (@navidcy) Rename return_metrics -> coordinates (#3257) (@navidcy) Update dependencies and use Julia 1.9.3 for CI (#3258) (@navidcy) (0.87.4) Add missing with_advective_forcing method (#3259) (@glwagner) Closed issues: Evolving perturbations vs total fields in Nonhydrostatic model (#3251) Rename return_metrics since it returns coordinates, not metrics (#3253) Metrics across ConformalCubedSphereGrid panels (#3254

    Engaging Caregivers and Providers of Children With Sickle Cell Anemia in Shared Decision Making for Hydroxyurea:Protocol for a Multicenter Randomized Controlled Trial

    No full text
    BACKGROUND: Sickle cell anemia (SCA) is a genetic blood disorder that puts children at a risk of serious medical complications, early morbidity and mortality, and high health care utilization. Until recently, hydroxyurea was the only disease-modifying treatment for this life-threatening disease and has remained the only option for children younger than 5 years. Evidence-based guidelines recommend using a shared decision-making (SDM) approach for offering hydroxyurea to children with SCA (HbSS or HbS/β0 thalassemia) aged as early as 9 months. However, the uptake remains suboptimal, likely because caregivers lack information about hydroxyurea and have concerns about its safety and potential long-term side effects. Moreover, clinicians do not routinely receive training or tools, especially those that provide medical evidence and consider caregivers’ preferences and values, to facilitate a shared discussion with caregivers. OBJECTIVE: The aim of this study is to understand how best to help parents of young children with sickle cell disease and their clinicians have a shared discussion about hydroxyurea (one that considers medical evidence and parent values and preferences). METHODS: We designed our study to compare the effectiveness of two methods for disseminating hydroxyurea guidelines to facilitate SDM: a clinician pocket guide (ie, usual care) and a clinician hydroxyurea SDM toolkit (H-SDM toolkit). Our primary outcomes are caregiver reports of decisional uncertainty and knowledge of hydroxyurea. The study also assesses the number of children (aged 0-5 years) who were offered and prescribed hydroxyurea and the resultant health outcomes. RESULTS: The Ethics Committee of the Cincinnati Children’s Hospital Medical Center approved this study in November 2017. As of February 2021, we have enrolled 120 caregiver participants. CONCLUSIONS: The long-term objective of this study is to improve the quality of care for children with SCA. Using multicomponent dissemination methods developed in partnership with key stakeholders and designed to address barriers to high-quality care, caregivers of patients with SCA can make informed and shared decisions about their health. TRIAL REGISTRATION: ClinicalTrials.gov NCT03442114; https://clinicaltrials.gov/ct2/show/NCT03442114 INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID): DERR1-10.2196/2765

    Engaging caregivers and providers of children with sickle cell anemia in shared decision making for hydroxyurea: Protocol for a multicenter randomized controlled trial

    No full text
    Background: Sickle cell anemia (SCA) is a genetic blood disorder that puts children at a risk of serious medical complications, early morbidity and mortality, and high health care utilization. Until recently, hydroxyurea was the only disease-modifying treatment for this life-threatening disease and has remained the only option for children younger than 5 years. Evidence-based guidelines recommend using a shared decision-making (SDM) approach for offering hydroxyurea to children with SCA (HbSS or HbS/β0 thalassemia) aged as early as 9 months. However, the uptake remains suboptimal, likely because caregivers lack information about hydroxyurea and have concerns about its safety and potential long-term side effects. Moreover, clinicians do not routinely receive training or tools, especially those that provide medical evidence and consider caregivers\u27 preferences and values, to facilitate a shared discussion with caregivers. Objective: The aim of this study is to understand how best to help parents of young children with sickle cell disease and their clinicians have a shared discussion about hydroxyurea (one that considers medical evidence and parent values and preferences). Methods: We designed our study to compare the effectiveness of two methods for disseminating hydroxyurea guidelines to facilitate SDM: a clinician pocket guide (ie, usual care) and a clinician hydroxyurea SDM toolkit (H-SDM toolkit). Our primary outcomes are caregiver reports of decisional uncertainty and knowledge of hydroxyurea. The study also assesses the number of children (aged 0-5 years) who were offered and prescribed hydroxyurea and the resultant health outcomes. Results: The Ethics Committee of the Cincinnati Children\u27s Hospital Medical Center approved this study in November 2017. As of February 2021, we have enrolled 120 caregiver participants. Conclusions: The long-term objective of this study is to improve the quality of care for children with SCA. Using multicomponent dissemination methods developed in partnership with key stakeholders and designed to address barriers to high-quality care, caregivers of patients with SCA can make informed and shared decisions about their health

    Are Good Managers Required for a Separation of Ownership and Control?

    No full text

    Towards a Geocentric Framework of Organizational Form: A Holistic, Dynamic and Paradoxical Approach

    No full text
    corecore